AMP-activated protein kinase and muscle glucose uptake.

The AMP-activated protein kinase (AMPK) is an enzyme that is activated in situations where there are changes in the cellular energy status such as muscle contraction and hypoxia. AMPK can also be pharmacologically activated by the compound 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) and the antidiabetic agent metformin. Several studies support the hypothesis that AMPK plays an important role in the stimulation of muscle glucose uptake by these physiological and pharmacological stimuli. In isolated rat muscles, activation of AMPK is associated with increases in glucose uptake through an insulin-independent mechanism. Studies done in rodents have shown that the activation of AMPK by AICAR is accompanied by decreases in blood glucose concentrations, in part due to enhanced muscle glucose uptake. Similar to exercise, AICAR not only directly stimulates glucose uptake into the skeletal muscle, but also enhances insulin sensitivity. The activation of AMPK and associated increases in muscle glucose uptake are affected by factors such as glycogen content, exercise training and fibre type. The effects of AMPK on muscle glucose uptake makes this protein a promising pharmacological target for the treatment of type 2 diabetes.

[1]  J. Zierath,et al.  Insulin action in skeletal muscle from patients with NIDDM , 1998, Molecular and Cellular Biochemistry.

[2]  J. Zierath,et al.  C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation , 1996, Diabetologia.

[3]  G. Cooney,et al.  AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. , 2002, Diabetes.

[4]  K. Walsh,et al.  Modulation by Peroxynitrite of Akt- and AMP-activated Kinase-dependent Ser1179 Phosphorylation of Endothelial Nitric Oxide Synthase* , 2002, The Journal of Biological Chemistry.

[5]  D. Hardie,et al.  The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. , 2002, Diabetes.

[6]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[7]  F. Agani,et al.  Role of nitric oxide in the regulation of HIF-1α expression during hypoxia , 2002 .

[8]  O. Pedersen,et al.  Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. , 2002, Diabetes.

[9]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[10]  L. Goodyear,et al.  Targeting the AMP-activated protein kinase for the treatment of type 2 diabetes. , 2002, Current drug targets. Immune, endocrine and metabolic disorders.

[11]  Robert V Farese,et al.  Activation of the ERK Pathway and Atypical Protein Kinase C Isoforms in Exercise- and Aminoimidazole-4-carboxamide- 1-β-d-riboside (AICAR)-stimulated Glucose Transport* , 2002, The Journal of Biological Chemistry.

[12]  E. Gulve,et al.  Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. , 2002, Biochemical and biophysical research communications.

[13]  B. Kemp,et al.  Role of 5′AMP‐activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease , 2002, The Journal of physiology.

[14]  T. Asano,et al.  Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. , 2002, American journal of physiology. Endocrinology and metabolism.

[15]  S. Baldwin,et al.  Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. , 2002, The Biochemical journal.

[16]  S. Mudaliar,et al.  Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. , 2002, Diabetes.

[17]  Y. Hellsten,et al.  Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. , 2002, Diabetes.

[18]  J. Zierath,et al.  5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice , 2002, Diabetologia.

[19]  D. Hardie,et al.  5′-AMP-activated Protein Kinase Phosphorylates IRS-1 on Ser-789 in Mouse C2C12 Myotubes in Response to 5-Aminoimidazole-4-carboxamide Riboside* , 2001, The Journal of Biological Chemistry.

[20]  D. Hardie,et al.  AMP‐activated protein kinase: the energy charge hypothesis revisited , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.

[21]  J. Zierath,et al.  5-aminoimidazole-4-carboxy-amide-1-β-D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAy-CETP mice , 2001, Diabetologia.

[22]  Jiahuai Han,et al.  Stimulation of Glucose Transport by AMP-activated Protein Kinase via Activation of p38 Mitogen-activated Protein Kinase* , 2001, The Journal of Biological Chemistry.

[23]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[24]  W. Winder.  Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. , 2001, Journal of applied physiology.

[25]  M. Bucan,et al.  A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. , 2001, Molecular cell.

[26]  G. Shulman,et al.  Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. , 2001, Diabetes.

[27]  O. Ljungqvist,et al.  AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. , 2001, Diabetes.

[28]  H. Galbo,et al.  Effect of force development on contraction induced glucose transport in fast twitch rat muscle. , 2001, Acta physiologica Scandinavica.

[29]  N. Fujii,et al.  Nitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle. , 2001, Diabetes.

[30]  O. Pedersen,et al.  Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. , 2001, Diabetes.

[31]  D. Hardie,et al.  Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. , 2000, Diabetes.

[32]  R. Somwar,et al.  Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport. , 2000, Diabetes.

[33]  B. Hansen,et al.  Isoform‐specific and exercise intensity‐dependent activation of 5′‐AMP‐activated protein kinase in human skeletal muscle , 2000, The Journal of physiology.

[34]  F. Ismail-Beigi,et al.  Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. , 2000, Archives of biochemistry and biophysics.

[35]  O. Ljungqvist,et al.  Exercise induces isoform-specific increase in 5'AMP-activated protein kinase activity in human skeletal muscle. , 2000, Biochemical and biophysical research communications.

[36]  L. Goodyear.  AMP‐Activated Protein Kinase: A Critical Signaling Intermediary for Exercise‐Stimulated Glucose Transport? , 2000, Exercise and sport sciences reviews.

[37]  N. Fujii,et al.  Activation of AMP-Activated Protein Kinase as a Unifying Coupling Mechanism , 2000 .

[38]  W. Winder,et al.  Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. , 1999, Journal of applied physiology.

[39]  Tatsuya Hayashi,et al.  Skeletal muscle contractile activity in vitro stimulates mitogen-activated protein kinase signaling. , 1999, American journal of physiology. Cell physiology.

[40]  L. Goodyear,et al.  5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. , 1999, Diabetes.

[41]  E. Horton,et al.  Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. , 1999, Diabetes.

[42]  P. Ortiz de Montellano,et al.  AMP‐activated protein kinase phosphorylation of endothelial NO synthase , 1999, FEBS letters.

[43]  B. Kemp,et al.  Dealing with energy demand: the AMP-activated protein kinase. , 1999, Trends in biochemical sciences.

[44]  T. Balon.  Integrative biology of nitric oxide and exercise. , 1999, Exercise and sport sciences reviews.

[45]  Tatsuya Hayashi,et al.  Evidence for 5′AMP-Activated Protein Kinase Mediation of the Effect of Muscle Contraction on Glucose Transport , 1998, Diabetes.

[46]  A. Baron,et al.  Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. , 1998, The Journal of clinical investigation.

[47]  M. Carlson,et al.  The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? , 1998, Annual review of biochemistry.

[48]  B. Hansen,et al.  Insulin Signaling in Human Skeletal Muscle: Time Course and Effect of Exercise , 1997, Diabetes.

[49]  G. Etgen,et al.  Nitric Oxide Stimulates Skeletal Muscle Glucose Transport Through a Calcium/Contraction– and Phosphatidylinositol-3-Kinase–Independent Pathway , 1997, Diabetes.

[50]  B. Rasmussen,et al.  Effect of exercise intensity on skeletal muscle malonyl-CoA and acetyl-CoA carboxylase. , 1997, Journal of applied physiology.

[51]  B. Kemp,et al.  Contraction-induced Changes in Acetyl-CoA Carboxylase and 5′-AMP-activated Kinase in Skeletal Muscle* , 1997, The Journal of Biological Chemistry.

[52]  J. Zierath,et al.  Insulin Receptor Substrate-1 Phosphorylation and Phosphatidylinositol 3-Kinase Activity in Skeletal Muscle From NIDDM Subjects After In Vivo Insulin Stimulation , 1997, Diabetes.

[53]  B. Kemp,et al.  Isoform-specific Purification and Substrate Specificity of the 5′-AMP-activated Protein Kinase* , 1996, The Journal of Biological Chemistry.

[54]  M. Vincent,et al.  Stimulation of rat liver AMP-activated protein kinase by AMP analogues. , 1996, Biochimica et biophysica acta.

[55]  B. Kemp,et al.  Mammalian AMP-activated Protein Kinase Subfamily (*) , 1996, The Journal of Biological Chemistry.

[56]  F. Giorgino,et al.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. , 1995, The Journal of clinical investigation.

[57]  J. Ivy,et al.  Contraction-activated glucose uptake is normal in insulin-resistant muscle of the obese Zucker rat. , 1992, Journal of applied physiology.

[58]  H. Beck-Nielsen,et al.  Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. , 1989, Acta endocrinologica.

[59]  G. Dohm,et al.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. , 1987, The Journal of clinical investigation.

[60]  R. DeFronzo,et al.  The Effect of Insulin on the Disposal of Intravenous Glucose: Results from Indirect Calorimetry and Hepatic and Femoral Venous Catheterization , 1981, Diabetes.